Colestipol hydrochloride prophylaxis of diarrhea during pelvic radiotherapy.
Thirty-three patients were randomized prior to pelvic radiotherapy to receive the bile acid-sequestering resin colestipol hydrochloride, 5 grams qid, during the entire time of their therapy or diphenoxylate hydrochloride and atropine sulfate 2.5-20 mg per day (control) if they experienced diarrhea. The colestipol patients also took diphenoxylate if they had diarrhea. The patients in the colestipol group often experienced nausea, vomiting, and abdominal cramps and 8 were forced to discontinue the drug. There was no difference in the weekly stool frequency between the colestipol and the control patients but the colestipol patients who took at least 50% of the prescribed dose required fewer diphenoxylate tablets than the controls. The data suggest that colestipol hydrochloride is not of value in preventing radiation-induced diarrhea because of the side effects associated with the drug, but the theory on which the use of bile acid-sequestering agents is based may be correct.
D000328:Adult; D000368:Aged; D003084:Colestipol / Q000009:adverse effects / Q000627:therapeutic use*; D003967:Diarrhea / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009120:Muscle Cramp / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D010388:Pelvis; D011073:Polyamines / Q000627:therapeutic use*; D011292:Premedication; D011878:Radiotherapy / Q000009:adverse effects*; D011897:Random Allocation; D014839:Vomiting / Q000139:chemically induced
D011073:Polyamines; D003084:Colestipol